David Wagner, PhD
Associate Professor, Medicine-Pulmonary Sciences & Critical Care
- Associate Professor
- Chief Scientific Officer
- Head, Immunology Section
Recognition & Awards
Philip R. Lee Award in Diabetes Research, American Diabetes Association
This award is given to the highest scoring Career Development Award Grant administered by the ADA. A typical year has over 400 applicants.
Faculty Advisor, PhD program
School of Medicine,
Immunology and Microbiology
Im interested in autoimmune regulation; defining pathogenic T cell subsets and controlling those. Specific disease areas include: Type 1 Diabetes, Multiple Sclerosis; Cardio-Vascular Disease/Atherosclerosis and Stroke.
Not available yet
"Understanding Inflammation During Type 1 Diabetes"
Frontiers in Neurology "Ocrelizumab Anti-CD20 Treatment Regulates TH40 Cells, A Biomarker of Systemic Inflammation, In All Disease Courses of Multiple Sclerosis" ON TIME
Enrique Alverez and
David H Wagner
Vaitaitis GM, Olmstead MH, Waid DM, Carter JR, Wagner DH Jr. CD40-targeted peptide proposed for type 1 diabetes therapy lacks relevant binding affinity to its cognate receptor. Reply to Pagni PP, Wolf A, Lo Conte M et al [letter]. Diabetologia. 2019 Sep;62(9):1730-1731. PubMed PMID: 31286154
Vaitaitis GM, Rihanek M, Alkanani AK, Waid DM, Gottlieb PA, Wagner DH. Biomarker discovery in pre-Type 1 Diabetes; Th40 cells as a predictive risk factor. J Clin Endocrinol Metab. 2019 May 7. [Epub ahead of print] PubMed PMID: 31063181
Vaitaitis GM, Yussman MG, Wagner DH Jr. A CD40 targeting peptide prevents severe symptoms in experimental autoimmune encephalomyelitis. J Neuroimmunol. 2019 Jul 15;332:8-15. PubMed PMID: 30925295
I am passionate about Mountain Biking and Road Biking in addition to fitness. I am a very good cook.
American Diabetes Association Community Leadership Board
I give regular talks on type 1 diabetes research areas. Also I am under consideration for TED talks X.